David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)
October 23, 2024 07:27 AM EDTUpdated 11:09 AM
Pharma

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Kyle LaHucik

Senior Reporter

Eli Lil­ly’s Alzheimer’s drug Kisun­la is like­ly to face an up­hill up­take bat­tle in the UK af­ter its lo­cal cost-ef­fec­tive­ness watch­dog NICE

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

Roche says it is un­de­terred by up­com­ing biosim­i­lar threat to Vabysmo

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times